Research ArticleArticles

Osteoporosis After Breast Cancer Chemotherapy: A Case Report

Giovanni Sisti and Olga Prontera
Ochsner Journal June 2009, 9 (2) 68-74;

REFERENCES

  1. ↵
    1. Nagai M. A.,
    2. Brentani M. M.
    (2008) Gene expression profiles in breast cancer to identify estrogen receptor target genes. Mini Rev Med Chem 8(5):448–454, pmid:18473934.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Nguyen P. L.,
    2. Taghian A. G.,
    3. Katz M. S.,
    4. et al.
    (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy [published correction appears in J Clin Oncol. 2008;26(18):3110]. J Clin Oncol 26(14):2373–2378, pmid:18413639.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Carey L. A.,
    2. Perou C. M.,
    3. Livasy C. A.,
    4. et al.
    (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492–2502, pmid:16757721.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Nadji M.,
    2. Gomez-Fernandez C.,
    3. Ganjei-Azar P.,
    4. Morales A. R.
    (2005) Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 123(1):21–27, pmid:15762276.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Ibrahim M.,
    2. Dodson A.,
    3. Barnett S.,
    4. Fish D.,
    5. Jasani B.,
    6. Miller K.
    (2008) Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory. Am J Clin Pathol 129(3):398–409, pmid:18285262.
    OpenUrlCrossRefPubMed
  6. ↵
    (1996) Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer: adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 14(10):2843–2877, pmid:8874347.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Anderson W. F.,
    2. Chatterjee N.,
    3. Ershler W. B.,
    4. Brawley O. W.
    (2002) Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 76(1):27–36, pmid:12408373.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Hede K.
    (2008) Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing. J Natl Cancer Inst 100(12):836–837, 844, pmid:18544732.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Yang T. S.,
    2. Chen Y. J.,
    3. Liang W. H.,
    4. et al.
    (2007) A clinical trial of 3 doses of transdermal 17β-estradiol for preventing postmenopausal bone loss: a preliminary study. J Chin Med Assoc 70(5):200–206, pmid:17524997.
    OpenUrlPubMed
  10. ↵
    1. Hadji P.
    (2008) Menopausal symptoms and adjuvant therapy-associated adverse events. Endocr Relat Cancer 15(1):73–90, pmid:18310277.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Gradishar W. J.
    (2005) Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. Oncology 69(1):1–9, pmid:16088229.
    OpenUrlPubMedWeb of Science
  12. ↵
    1. Folkestad L.,
    2. Bjarnason N. H.,
    3. Bjerregaard J. K.,
    4. Brixen K.
    (2009) The effect of aromatase inhibitors on bone metabolism. Basic Clin Pharmacol Toxicol 104(1):3–10, pmid:19152547.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Conte P.,
    2. Frassoldati A.
    (2007) Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: putting safety issues into perspective. Breast J 13(1):28–35, pmid:17214790.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Murray N.,
    2. Winstanley J.,
    3. Bennett A.,
    4. Francis K; Guideline Development Group
    (2009) Diagnosis and treatment of advanced breast cancer: summary of NICE guidance. BMJ 338:b509. doi: 10.1136/bmj.b509, pmid:19244303.
    OpenUrlPubMed
  15. ↵
    1. Coleman R. E.,
    2. Banks L. M.,
    3. Girgis S. I.,
    4. et al.
    (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8(2):119–127, pmid:17267326.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Gonnelli S.,
    2. Cadirni A.,
    3. Caffarelli C.,
    4. et al.
    (2007) Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 40(1):205–210, pmid:16904960.
    OpenUrlPubMed
  17. ↵
    1. Mincey B. A.,
    2. Duh M. S.,
    3. Thomas S. K.,
    4. et al.
    (2006) Risk of cancer treatment–associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer 7(2):127–132, pmid:16800971.
    OpenUrlPubMed
  18. ↵
    1. Bundred N. J.
    (2009) Aromatase inhibitors and bone health. Curr Opin Obstet Gynecol 21(1):60–67, pmid:19125005.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Adler R. A.
    (2007) Cancer treatment-induced bone loss. Curr Opin Endocrinol Diabetes Obes 14(6):442–445, pmid:17982349.
    OpenUrlPubMed
  20. ↵
    1. Reid D. M.,
    2. Doughty J.,
    3. Eastell R.,
    4. et al.
    (2008) Guidance for the management of breast cancer treatment–induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 34(suppl 1):S3–S18, pmid:18515009.
    OpenUrlPubMed
  21. ↵
    1. Coxon F. P.,
    2. Thompson K.,
    3. Roelofs A. J.,
    4. et al.
    (2008) Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 42(5):848–860. Epub 2008 Jan 26, pmid:18325866.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Brufsky A.
    (2006) Management of cancer-treatment–induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin Oncol 33(2):S13–S17, pmid:16730272.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Reeves K. W.,
    2. Faulkner K.,
    3. Modugno F.,
    4. et al.
    (2007) Body mass index and mortality among older breast cancer survivors in the Study of Osteoporotic Fractures. Cancer Epidemiol Biomarkers Prev 16(7):1468–1473, pmid:17627012.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Irwin M. L.,
    2. McTiernan A.,
    3. Baumgartner R. N.,
    4. et al.
    (2005) Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol 23(4):774–782, pmid:15681521.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Hadji P.,
    2. Gottschalk M.,
    3. Ziller V.,
    4. Kalder M.,
    5. Jackisch C.,
    6. Wagner U.
    (2007) Bone mass and the risk of breast cancer: the influence of cumulative exposure to oestrogen and reproductive correlates: results of the Marburg Breast Cancer and Osteoporosis Trial (MABOT). Maturitas 56(3):312–321, pmid:17049767.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Brinton L. A.,
    2. Richesson D. A.,
    3. Gierach G. L.,
    4. et al.
    (2008) Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst 100(20):1477–1481, pmid:18840816.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Burshell A. L.,
    2. Song J.,
    3. Dowsett S. A.,
    4. et al.
    (2008) Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis. Curr Med Res Opin 24(3):807–813, pmid:18254988.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Nabholtz J. M.
    (2008) Aromatase inhibitors in the management of early breast cancer. Eur J Surg Oncol 34(11):1199–1207, pmid:18359182.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords